CJC-1295 with Drug Affinity Complex (DAC) is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) designed for extended pharmacokinetic retention in preclinical models. By covalently bioconjugating to circulating serum albumin via a reactive maleimide linker, CJC-1295 DAC dramatically prolongs systemic availability while maintaining selective GHRH receptor activation.
CJC-1295 with Drug Affinity Complex (DAC) is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) designed for extended pharmacokinetic retention in preclinical models. By covalently bioconjugating to circulating serum albumin via a reactive maleimide linker, CJC-1295 DAC dramatically prolongs systemic availability while maintaining selective GHRH receptor activation.
CJC-1295 with Drug Affinity Complex (DAC) represents a chemically modified iteration of human growth hormone-releasing hormone (GHRH 1-29). The foundational sequence incorporates targeted amino acid substitutions at positions 2, 8, 15, and 27 to reduce susceptibility to rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV). However, the defining structural innovation of CJC-1295 DAC is the covalent addition of a lysine residue attached to a reactive maleimidopropionic acid moiety at the C-terminus.
In physiological or laboratory buffers containing albumin, this maleimide functional group selectively reacts with the free thiol group on Cys34 of circulating serum albumin. This irreversible bioconjugation prevents rapid renal clearance and protects the peptide core from enzymatic breakdown. Researchers evaluating growth hormone secretagogues routinely utilize CJC-1295 DAC to model sustained, non-pulsatile GHRH receptor stimulation over multi-day experimental windows.
For investigators seeking reference standards, PX1 Research provides fully characterized CJC-1295 DAC synthesized under strict quality controls to ensure consistent bioactivity and structural integrity across diverse assays.
The core functionality of the Drug Affinity Complex (DAC) relies on reactive bioconjugation chemistry. Unmodified peptide hormones typically exhibit short plasma half-lives due to rapid cleavage by circulating peptidases and rapid glomerular filtration in the kidneys. By introducing a chemical reactive group (3-maleimidopropionic acid) linked via a lysyl spacer, the peptide undergoes spontaneous covalent binding upon entering an aqueous biological environment containing albumin.
Endogenous serum albumin acts as a macromolecular carrier. Because albumin possesses an extended half-life in mammalian circulation (approximately 19 to 20 days in humans, and several days in rodent models), the conjugated CJC-1295 moiety acquires these modified clearance dynamics. The resulting conjugate remains capable of interacting with the GHRH receptor on anterior pituitary somatotrophs, driving sustained transcriptional activation without requiring continuous intravenous infusion.
Understanding this chemistry is critical when conducting comparative work across all research peptides targeting endocrine receptors, as covalent carrier binding fundamentally alters classical ligand-receptor association and dissociation kinetics.
At the cellular level, CJC-1295 DAC acts as a potent agonist at the GHRH receptor, a seven-transmembrane G-protein-coupled receptor (GPCR) predominantly expressed on the cell surface of anterior pituitary somatotrophs. Ligand binding triggers a conformational change in the receptor that activates heterotrimeric Gs proteins, subsequently stimulating transmembrane adenylyl cyclase.
Adenylyl cyclase activation leads to an intracellular accumulation of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels activate protein kinase A (PKA), which phosphorylates the cAMP-response element-binding protein (CREB). Translocation of phosphorylated CREB to the nucleus promotes the transcription of genes encoding growth hormone (GH) as well as the GHRH receptor itself.
Simultaneously, the PKA pathway opens voltage-dependent calcium channels, facilitating extracellular calcium influx that stimulates the exocytosis of pre-stored GH secretory vesicles. In laboratory models, this mechanism results in sustained downstream production of insulin-like growth factor 1 (IGF-1) from hepatic and peripheral tissues, providing a robust experimental framework for studying long-term endocrine modulation.
The primary distinction between CJC-1295 with DAC and non-DAC peptide analogs (such as Modified GRF 1-29 or Sermorelin) lies in their elimination half-lives and plasma retention curves. Non-DAC GHRH analogs exhibit an elimination half-life typically measured in minutes (approximately 8 to 30 minutes in rodent and canine models), requiring frequent administration to maintain target receptor occupancy.
In contrast, preclinical pharmacokinetic evaluations demonstrate that CJC-1295 DAC exhibits an extended half-life ranging from 6 to 8 days in animal models, depending on species-specific albumin turnover rates. This persistent presence leads to baseline elevation of circulating GH and IGF-1 levels rather than distinct, discrete secretory spikes.
Researchers choosing between these modalities must align their selection with experimental goals. Studies focusing on physiological, rhythmic GH pulses often favor short-acting secretagogues like Ipamorelin or Modified GRF (1-29), whereas studies requiring constant, sustained systemic IGF-1 elevation prioritize long-acting compounds such as CJC-1295 DAC.
In vitro and animal model studies have evaluated CJC-1295 DAC across various experimental paradigms centered on tissue regeneration, protein synthesis, and metabolic homeostasis. Because growth hormone and downstream IGF-1 play vital roles in cellular proliferation, extracellular matrix remodeling, and nitrogen retention, long-acting GHRH agonists serve as valuable tools in wound healing and musculoskeletal research.
Preclinical rodent models evaluating musculoskeletal recovery indicate that sustained IGF-1 receptor activation via CJC-1295 DAC enhances satellite cell proliferation and collagen mRNA expression in injured tendon and skeletal muscle tissue. Furthermore, research models exploring lipid metabolism demonstrate that continuous GHRH receptor signaling increases lipolysis in adipose tissue while preserving lean tissue mass during catabolic states.
Investigators exploring synergistic receptor pathways frequently pair GHRH analogs with ghrelin receptor agonists to study dual-pathway somatotroph stimulation. Detailed scientific context regarding these multi-target approaches can be explored within our research library hub.
To select the appropriate tool for laboratory investigations, researchers must evaluate how CJC-1295 DAC compares to other common peptides in the GHRH and secretagogue classes. The table and comparative points below outline the primary functional differences observed in preclinical literature:
1. **CJC-1295 DAC**: Extended-duration GHRH agonist (half-life ~6-8 days in vivo). Induces persistent, baseline elevation of GH and IGF-1. 2. **Modified GRF (1-29)**: Short-acting GHRH agonist (half-life ~30 minutes). Preserves natural pulsatile GH release when co-administered with GHRPs. 3. **Sermorelin**: Truncated native GHRH sequence (1-29 amide). Rapidly degraded by DPP-IV; useful for transient receptor activation dynamics. 4. **Ipamorelin**: Selective GHRP/Ghrelin receptor agonist. Works via a distinct receptor pathway (GHS-R1a) without activating cortisol or prolactin pathways.
When designing protocols requiring institutional review or precise mass balance studies, selecting the correct half-life profile ensures minimal confounding variables during data collection.
Given the structural complexity of modified peptides incorporating C-terminal maleimide functional groups, rigorous analytical validation is required to ensure peptide identity, chemical purity, and stability. Imprecise synthesis or improper handling can lead to premature maleimide hydrolysis, rendering the Drug Affinity Complex incapable of albumin binding.
PX1 Research subjects every production lot of CJC-1295 DAC to comprehensive analytical screening. Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) is utilized to confirm chemical purity standards exceeding 98%. Simultaneously, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular weight and structural integrity of the peptide-linker conjugate.
Furthermore, biological assays intended for cellular or animal models demand stringent endotoxin testing. PX1 Research enforces strict bacterial endotoxin limits (<0.01 EU/mg) verified via Chromogenic LAL testing, ensuring that research materials do not induce non-specific inflammatory responses in delicate cell cultures or in vivo models.
Proper reconstitution and handling procedures are essential to maintain the structural integrity of CJC-1295 DAC in laboratory environments. Lyophilized peptide vials should be stored at -20°C or -80°C upon receipt to prevent hydrolytic degradation over extended periods.
When preparing solutions for in vitro or preclinical assays, the vial should be allowed to equilibrate to room temperature prior to reconstitution to minimize condensation inside the container. Reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile endotoxin-free phosphate-buffered saline (PBS), depending on the requirements of the biological assay.
Gently swirl or invert the vial to solubilize the cake; mechanical agitation or vigorous shaking should be strictly avoided to prevent peptide aggregation or shear-induced denaturation. Once reconstituted, liquid aliquots should be stored at 2°C to 8°C for short-term use (up to 30 days) or sub-aliquoted and frozen at -80°C to avoid repeated freeze-thaw cycles.
Procuring high-grade research peptides requires working with suppliers that provide full lot-specific transparency and verified manufacturing controls. PX1 Research operates fully within GMP-compliant, ISO 17025 accredited laboratory environments based in the United States.
Every reagent supplied by PX1 Research includes an accessible, lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectrum verification, and quantitative endotoxin levels. Laboratories managing high-throughput screening or continuous animal protocols can apply for expanded laboratory accounts and volume sourcing through our wholesale peptide program.
All materials supplied by PX1 Research are strictly designated for laboratory research use only and are not intended for human or veterinary diagnostic, therapeutic, or clinical applications. Fast, secure dispatch from our California and Arizona logistics centers ensures compound stability and uninterrupted experimental workflows.
What is the primary function of the Drug Affinity Complex (DAC) in CJC-1295?
The Drug Affinity Complex (DAC) is a maleimide-bearing linker covalently attached to the peptide. It selectively binds to circulating serum albumin (Cys34) in vivo or in albumin-containing media, protecting the peptide from rapid enzymatic cleavage and renal filtration, thereby significantly extending its elimination half-life.
How does CJC-1295 DAC differ from Modified GRF (1-29)?
While both compounds are GHRH receptor agonists sharing similar modified core amino acid sequences, CJC-1295 DAC contains the C-terminal maleimide linker that binds albumin, extending its half-life to several days. Modified GRF (1-29) lacks this linker and exhibits a short half-life of approximately 30 minutes, producing discrete GH spikes rather than sustained elevation.
What purity verification standards does PX1 Research provide for CJC-1295 DAC?
Every lot of CJC-1295 DAC undergoes independent third-party analytical testing, including Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm ≥98% purity, Mass Spectrometry (MS) for structural identity, and LAL assays to ensure endotoxin levels remain below 0.01 EU/mg.
What solvent is recommended for reconstituting CJC-1295 DAC for laboratory use?
For standard analytical and cellular research, sterile Bacteriostatic Water or sterile endotoxin-free physiological saline (PBS) is recommended. The appropriate solvent choice depends on the specific in vitro assay parameters and storage duration requirements.
How should lyophilized CJC-1295 DAC be stored upon receipt?
Lyophilized CJC-1295 DAC should be kept frozen at -20°C or -80°C in a dry environment away from light. Under these conditions, the peptide remains stable for up to 24 months.
Does CJC-1295 DAC alter normal GH pulsatility in animal models?
Yes. Preclinical studies indicate that continuous activation of GHRH receptors via CJC-1295 DAC leads to sustained, non-pulsatile baseline elevations in growth hormone and IGF-1, whereas short-acting GHRH analogs preserve distinct pulsatile release patterns.
Are PX1 Research products suitable for clinical or veterinary use?
No. All products offered by PX1 Research, including CJC-1295 DAC, are strictly formulated and sold for laboratory in vitro and preclinical research use only. They are not intended for human or clinical consumption, therapeutic use, or administration to animals outside of approved research protocols.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.